When was Pathos founded?

Pathos was founded in 2022 and became a unicorn in 2025, reaching the milestone in 3 years. It raised its 1st funding round 2 years after its incorporation.

Where is Pathos located?

Pathos is headquartered in Chicago, United States.

How many employees does Pathos have?

As of Aug 31, 2026, the latest employee count at Pathos is 98.

Is Pathos a funded company?

Pathos is a funded company, having raised a total of $345M across 2 funding rounds to date. The company's 1st funding round was a $62M Series C round, raised on Oct 24, 2024.

How much is Pathos worth?

The latest valuation of Pathos is $3B as of Aug 03, 2026.

When was the latest funding round of Pathos?

Pathos' latest funding was a $283M Series D round on Apr 17, 2025, with participation from 0 investor. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $3.49B in funding in 2026 to date.

Is Pathos a Life Sciences Tech company?

The primary sectors of Pathos are Life Sciences Tech and Oncology.

Where does Pathos rank among its competitors?

Pathos ranks 258th amongst 3378 active competitors, of which 1131 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Pathos?

Pathos' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Pathos - 2026 Company Profile, Team, Funding & Competitors

Sectors and market segments that Pathos operate in

Pathos serves in the HealthTech, Life Sciences market segments.The primary business model of Pathos are:

Company Details

Provider of AI based drug discovery platform for drug development. The company licenses or co develops clinical stage therapeutics, optimizing patient selection strategies for accelerated, biomarker driven drug development. It utilizes real world oncology data and patient derived functional genomic data to identify and validate compelling biology, aiming to develop efficacious drugs for patients with unmet needs and enhance patient outcomes.

Key Metrics

Founded Year

2022

Location

Chicago, United States

Stage

Series D

Total Funding

$345M in 2 rounds

Latest Funding Round

Series D, Apr 17, 2025, $283M

Post Money Valuation

$3B as on Aug 03, 2026

Investors

New Enterprise Associates & 3 more

Ranked

258^th among 3378 active competitors

Employee Count

98 as on Aug 31, 2026

Investment & Acquisitions

DeuterOncology & 1 more

Similar Companies

Jazz Pharmaceuticals & 3025 more

View Pathos' full profile

Pathos has raised a total funding of $345M over 2 rounds. Its first funding round was on Oct 24, 2024. Pathos has 4 institutional investors.

Here is the list of recent funding rounds of Pathos:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 17, 2025	$283M	Series D	$1.6B	-	-	-
Oct 24, 2024	$62M	Series C	$600M	-	New Enterprise Associates	Revolution, Lightbank, Builders VC

Access funding benchmarks and valuations. Sign up today!

View details of Pathos's funding rounds and investors

The founders of Pathos are Ryan Fukushima and Eric Lefkofsky. Iker Huerga is the CEO of Pathos.

Here are the details of Pathos' key team members:

Ryan Fukushima: Co-Founder of Pathos. They are also an angel investor in 1 startup.
Contact Info: 1 email address
Eric Lefkofsky: Co-Founder of Pathos.
Contact Info: 1 email address
Iker Huerga: CEO of Pathos.
Contact Info: 1 email address

View details of Pathos's Founder profiles and Board Members

Pathos' employee count trend

Pathos has 98 employees as of Aug 26. Here is Pathos's employee count trend over the years:

Uncover Pathos' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pathos include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Pathos, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
258th	Pathos 2022, Chicago (United States), Series D	Provider of AI based drug discovery platform for drug development	$345M	Revolution, New Enterprise Associates & 2 others	58/100